While biotechnology companies and academic institutions in established markets remain important sources of innovation for pharmaceutical companies looking for licensing deals and partnerships, emerging markets are becoming increasingly attractive. This is especially true as pharma companies face patent expirations and increasing competition. Join business development executives from top pharmaceutical companies who will describe their company’s strategy in partnering with companies in emerging markets; why emerging markets appeal to them; which areas they are interested in and why; and whether the criteria to evaluate potential partnerships and collaborations in emerging markets differ from other deal types.
- Examine the role emerging markets play in pharma’s business development strategies
- Discover how Big Pharma accesses and assesses innovation in emerging markets
- Identify desirable attributes to get noticed by Big Pharma
Ability Level: All
Session ID: 1970